Loading…
Samrat Pharmachem (BSE 530125)₹257.95−0.02%Pharmaceuticals
At the end of the Jun 2026 quarter, Samrat Pharmachem's shareholders were: promoters 49.10%, FIIs 3.22%, public 47.68%. Promoter holding is unchanged on the quarter. FII holding is up 3.22 percentage points from 0.00% a year earlier. 0.00% of promoter shares were pledged. It had 6,328 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 48.65% | 48.65% | 48.65% | 48.65% | 48.96% | 49.10% | 49.10% | 49.10% | 49.10% | 49.10% | 49.10% | 49.10% |
| FIIs | 3.22% | 3.22% | 3.22% | 3.22% | 3.22% | 3.22% | 3.22% | 0.00% | 3.22% | 3.22% | 3.22% | 3.22% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.22% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 48.13% | 48.13% | 48.13% | 48.13% | 47.82% | 47.68% | 47.68% | 47.68% | 47.68% | 47.68% | 47.68% | 47.68% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 8,442 | 8,062 | 7,475 | 7,166 | 6,981 | 6,841 | 6,782 | 6,749 | 6,697 | 6,486 | 6,309 | 6,328 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Lalit Damodar Mehta | Promoter | 13.91% | 0.00 |
| Rajesh Lalit Mehta | Promoter | 12.43% | 0.00 |
| Premal Lalit Mehta | Promoter | 5.66% | 0.00 |
| Kaushal Lalit Mehta | Promoter | 4.53% | 0.00 |
| Jaya Lalit Mehta | Promoter | 3.89% | 0.00 |
| Sangeetha S | Public | 3.26% | 0.00 |
| Rupal Rajesh Mehta | Promoter | 2.65% | 0.00 |
| Falguni Kaushal Mehta | Promoter | 2.13% | 0.00 |
| Megh Rajesh Mehta | Promoter | 1.77% | 0.00 |
| Kalpana Premal Mehta | Promoter | 1.63% | 0.00 |
| Lalit Kumar V Jain | Public | 1.23% | 0.00 |
| Sharad Kanayalal Shah | Public | 1.12% | 0.00 |
| Maitri Megh Mehta | Promoter | 0.47% | 0.00 |
| Lloyds Securities Overseas Limited | FII | Exited | — |
| Anshul Specialty Molecules | Public | Exited | — |
Promoters held 49.10% of Samrat Pharmachem at the end of the Jun 2026 quarter, the same as a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 3.22% (unchanged at 3.22% a quarter earlier) and domestic institutions (DIIs) held 0.00% (unchanged at 0.00% a quarter earlier).
No. The Jun 2026 filing shows no pledged promoter shares.
Samrat Pharmachem had 6,328 shareholders at the end of the Jun 2026 quarter, against 6,749 a year earlier.
Sangeetha S (Public) held 3.26% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.